NEW YORK, January 3, 2026, 10:33 ET — Market closed
- Eli Lilly shares ended the last session higher, then eased slightly in late trading.
- Drug pricing is back in focus at the start of the year, with Medicare negotiations and list-price resets in the spotlight.
- Investors are watching upcoming conference remarks, the next earnings update, and key U.S. data releases.
Eli Lilly and Company shares closed up 0.53% at $1,080.36 on Friday and were down 0.17% in after-hours trading at $1,078.50.
The move matters because early January is when many drugmakers reset “list prices” — the published prices before rebates and insurer discounts — and those changes can shape negotiations with payers. Policy pressure on drug costs has also intensified as the new year begins.
For Lilly, pricing headlines can carry outsized weight. The company’s growth narrative is closely tied to high-demand diabetes and obesity medicines, leaving investors sensitive to any sign that access terms or net pricing are tightening.
Zacks Research upgraded Lilly to a “strong-buy” from “hold” in a note issued on Thursday, MarketBeat reported. MarketBeat
Reuters reported that drugmakers planned U.S. list-price increases on at least 350 branded medicines for 2026, with a median hike around 4%, while also cutting list prices on about nine drugs — including a more than 40% reduction for the diabetes drug Jardiance, which Lilly sells with Boehringer Ingelheim. “These deals are being announced as transformative when, in fact, they really just nibble around the margins,” said Dr. Benjamin Rome, a health policy researcher at Brigham and Women’s Hospital, in the Reuters report.
The broader market finished higher on Friday, with the S&P 500 gaining 0.19% and the Dow rising 0.66%, while big pharma names also advanced. Merck climbed 1.13% and Pfizer added 1.12%, with Lilly up 0.53%, according to MarketWatch data.
Even modest moves in Lilly can reverberate across the group because the stock sits at the center of the market’s obesity and diabetes trade. Traders have also been watching whether drug pricing actions aimed at Medicare and cash-paying patients spill over into broader commercial terms.
On a one-year view, Lilly has traded in a 52-week range of $623.78 to $1,111.99, putting Friday’s close about 3% below that high-water mark.
Before the next session, attention shifts to management commentary. Lilly said it will participate in the J.P. Morgan Healthcare Conference, where CEO David Ricks is scheduled to speak on January 13 at 5:15 p.m. ET.
Lilly’s investor schedule lists its fourth-quarter results call for February 4 at 10:00 a.m. EST, a key checkpoint for guidance and any updated color on pricing, access and demand.
Macro could also steer sentiment in the week ahead, with the U.S. employment report due January 9 and CPI set for January 13, while the Federal Reserve’s next policy meeting is scheduled for January 27-28.
On the charts, Lilly’s last session ranged from $1,052.08 to $1,080.66, with about 2.45 million shares traded; recent highs near $1,085 are another level traders reference. Support is a price zone where buyers tend to step in, while resistance is an area where selling often emerges.
